This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Health Care Fortnight for the Record Books

NEW YORK ( TheStreet) -- I've been a professional investor for 15 years, and over that time I've listened to generalist investors gripe about the health care sector with mind-numbing cyclicality. Predictably, interest in health care investing often hits a nadir at the time of greatest opportunity. The complaints, which typically arise after major biotech blowups or government policy-fueled anxiety, range from absurdly broad-based assertions of disinterest (health care is "un-investable" is a common refrain) to specific anxiety about the sector's dependence on government as a payor.

Investors who dismiss the health care stocks often do so because they lack the expertise required to understand the sector. They're missing a lot. For those who think -- or have ever thought -- health care isn't a great sector for alpha generation, I present the first half of May in the year 2012, one of the busiest and most exciting two weeks for health care in recent memory. This week's column reviews -- in the first of two parts -- key events and the implications for relevant companies.

The Bapi Time Bomb Approaches

On Pfizer's (PFE - Get Report) Q2'12 call, management revealed that the first of four massive Phase III trials of bapineuzumab -- the infamous amyloid beta-targeted monoclonal antibody initially developed by Elan (ELN) for Alzheimer's disease -- has been completed. This study, led by syndicate partner Johnson & Johnson (JNJ), enrolled 1,121 mild-to-moderate Alzheimer's patients with an unfavorable genetic mutation, called ApoE4, to receive either "bapi" or placebo.

Importantly, Pfizer said it plans to wait until the third quarter to disclose top line results from this trial alongside those from a second Phase III trial, which includes patients without the ApoE4 mutation. The non-carrier trial should be completed in August. As a reminder, the whole ApoE4 carrier versus non-carrier split was born from the post-hoc data mining of Elan's flagrantly equivocal Phase II trial.

Bulls insist the non-carrier study is more likely to succeed, because ApoE4 carriers with Alzheimer's are "too far gone" despite having clinically identical mild-to-moderate disease as the non-carriers. I still don't get why carriers, who have a worse prognosis, wouldn't respond better to a drug targeting amyloid beta, the alleged bad actor. Faulty logic.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
ELN $0.00 0.00%
GILD $112.13 0.82%
PFE $34.37 0.03%
VRTX $124.94 -0.09%
AAPL $132.38 0.75%

Markets

DOW 18,229.62 -56.12 -0.31%
S&P 500 2,126.92 -3.90 -0.18%
NASDAQ 5,088.7560 -2.0380 -0.04%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs